These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25645660)

  • 1. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
    Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
    Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
    Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration.
    Morris AA; Mueller SW; Rower JE; Washburn T; Kiser TH
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6653-6. PubMed ID: 26259790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
    Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
    Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.
    Luke DR; Wood ND; Tomaszewski KE; Damle B
    Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
    Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
    J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
    Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
    Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?
    Honore PM; Jacobs R; Hendrickx I; De Waele E; Van Gorp V; Spapen HD
    Crit Care; 2015 May; 19(1):234. PubMed ID: 26013496
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).
    Luke DR; Tomaszewski K; Damle B; Schlamm HT
    J Pharm Sci; 2010 Aug; 99(8):3291-301. PubMed ID: 20213839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
    von Mach MA; Burhenne J; Weilemann LS
    BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citrate clearance in children receiving continuous venovenous renal replacement therapy.
    Chadha V; Garg U; Warady BA; Alon US
    Pediatr Nephrol; 2002 Oct; 17(10):819-24. PubMed ID: 12376810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient.
    Quintard H; Papy E; Massias L; Lasocki S; Arnaud P; Desmonts JM; Montravers P
    Ther Drug Monit; 2008 Feb; 30(1):117-9. PubMed ID: 18223474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
    Fish DN; Teitelbaum I; Abraham E
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin removal by continuous venovenous hemofiltration.
    Oltrogge KM; Peppard WJ; Saleh M; Regner KR; Herrmann DJ
    Ann Pharmacother; 2013 Sep; 47(9):1218-22. PubMed ID: 24259740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.